Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3b, Open Label, Uncontrolled, Single-arm, Single-centre Study to Evaluate the Safety of Two Doses of Novartis Meningococcal Group B Vaccine When Administered to Healthy Adults From 18 to 50 Years of Age and to Collect Blood Donations to Develop Vaccines Against Neisseria Meningitidis

NCT02305446 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT02305446
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02305446 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3b, Open Label, Uncontrolled, Single-arm, Single-centre Study to Evaluate the Safety of Two Doses of Novartis Meningococcal Group B Vaccine When Administered to Healthy Adults From 18 to 50 Years of Age and to Collect Blood Donations to Develop Vaccines Against Neisseria Meningitidis
Lead sponsor
Novartis
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2014
Completion date
April 30, 2015
Enrollment
55 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

meningitis, meningococcal, serogroup b